Conference program

We will update and add the program as soon as it is defined:

Location: Hotel Suisse Majestic

Sunday, May 26th 2024 | Monday, May 27th 2024 | Tuesday, May 28th 2024

» REGISTER NOW «

Sunday, May 26^th 2024

14:00 - 15:30	Pre-Conference Workshop A board, really? A Board, indeed! Insights on the role of the board for biotech start-ups and on key attributes of board members Nathalie Rowell, CEO & Founder Virdis Group
15:30 onwards	Conference Registration / Check-In
16:00 - 17:00	Welcome Coffee & Networking
17:15 - 18:45	Keynote Synergies in the biopharma ecosystem: Navigating the future of pharma, biotech and VC Avaleigh Milne, Head of BD for Pharma Research & Early Development at Roche Keynote Biopharma dealmaking: Time for a rethink? Ed Saltzman, Senior Strategic Advisor at Lumanity Discussion and Q&A led by Nigel Sheail, Venture Partner, Versant Venture
18:45 - 19:15	Ice-breaker Chris Isler and Tytus Litynski, Swiss HLG Board Members
19:15 - 21:15	Kick-off dinner
21:15 - onwards	Networking with peers - meet at Funky Claude’s Bar Fairmont Le Montreux Palace

Monday, May 27^th 2024

07:00	Voluntary pre-conference morning run (meet at reception)
08:30 – 09:00	Swiss HLG General Assembly – members by invitation
09:00 - 09:10	Welcome & housekeeping Intro - To maximize your returns: portfolio strategy or opportunistic deals? Francesca Lianza, Swiss HLG Board Member
09:00 - 12:20	Empowering women’s health: Crafting a winning business strategy Michael John Chiusolo, Executive Director Global Marketing, Commercial Lead, Women’s Health at Organon Endogena Therapeutics – a novel drug discovery & development paradigm Mats Steger, CEO at ENDOGENA THERAPEUTICS How to build a multi-billion dollar biotech through partnering, an introduction to Roivant Sciences Christian Mauriand, Global Head of Corporate Development at Roivant Sciences
12:20 - 13:45	Lunch
13:45 - 17:00	At the intersection of biotech financing and pharma dealmaking Frederik Schmachtenberg, EY Global Life Sciences Lead for Financial Accounting Advisory Services at EY Deal Financing: Spotlighting recent M&A transactions Juliana Mazza-Reis, Global Senior Director, Mergers & Acquisitions (M&A) at Novartis Panel: where is the money coming from? Moderator: Nadine Maalouf, Managing Director at Van Lanschot Kempen Monique Schiersing, Senior Investment Director at Roche Venture Fund Andreas Wallnöfer, Partner & Investor at Jeito Capital Frank Hensel, Principal/Authorized signatory at HTGF Odile Rundquist, Advisor at Bioqube Ventures
18:00	Swiss HLG networking dinner
22:15 - onwards	Networking with peers - meet at Funky Claude’s Bar Fairmont Le Montreux Palace

Tuesday, May 28^th 2024

07:00	Voluntary pre-conference morning run (meet at reception)
09:00 - 09:05	Welcome & Housekeeping Intro - How is AI impacting business development? Ragip Ziyal, Swiss HLG Board Member
09:05 - 11:35	AI as catalyst in portfolio and deal decisions Tomas Khorel, Principal \| IQVIA X (AI-ML CoE)/ Strategy Consulting EMEA at IQVIA Transforming drug discovery with end-to-end Generative AI Michelle Chen, Chief Business Officer at Insilico Medicine The future of AI enabled drug discovery Richard Law, Chief Business Officer at Exscientia
11:35 - 12:00	Closing Key Note The inflection point we’ve been holding our breath for - is AI finally here? Thomas Devenyns, Associate Partner at McKinsey & Company
12:00 - 12:15	Closing remarks
12:10 - 13:30	Farewell Lunch & Networking

» REGISTER NOW «